Testing effectiveness (Phase 2)Looking for participantsNCT05418010
What this trial is testing
Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
Who this might be right for
Multiple SclerosisClinically Isolated Syndrome of Demyelination
Queen Mary University of London 40